A study is a beginning.
Ask the next question.
A useful research summary answers five questions: who was studied, what they took, what it was compared with, what changed, and what remains uncertain.
01 / Who was actually studied?
A study in people with elevated cardiovascular risk does not automatically describe what happens in healthy adults. Look for age, existing conditions, background treatment, and baseline omega-3 status.
02 / What exactly was the intervention?
“Fish oil” can obscure the dose and formulation. REDUCE-IT tested 4 g/day of prescription icosapent ethyl in statin-treated patients. STRENGTH tested 4 g/day of an EPA/DHA carboxylic-acid formulation. These are different interventions.
03 / Compared with what?
Placebo composition, background diet, and standard medical care matter. REDUCE-IT used mineral oil; STRENGTH used corn oil. The trials cannot be treated as a direct head-to-head comparison of EPA and DHA.
04 / What changed—and by how much?
In REDUCE-IT, the primary endpoint occurred in 17.2% versus 22.0% of participants over a median 4.9 years: a 4.8 percentage-point absolute difference. The reported 25% relative reduction is based on the time-to-event analysis. STRENGTH found no significant reduction in its primary cardiovascular endpoint.
05 / What is the cost of the benefit?
Read adverse events alongside efficacy. Both trials reported an atrial-fibrillation signal. A favorable biomarker alone cannot establish that a treatment prevents disease. Funding and study limitations belong in the interpretation too.
What this means for you
Use a study to ask a more specific question—not to choose a high dose on your own. A clinician can help decide whether its population and intervention apply to your situation.
Read the originals
REDUCE-IT · Bhatt et al., NEJM, 2019
STRENGTH · Nicholls et al., JAMA, 2020
NIH · Omega-3 health professional fact sheet